IPP Bureau
Nipah survivors study to advance new vaccines against highly fatal threat
By IPP Bureau - March 16, 2022
CEPI will expand its partnership with icddr,b in Bangladesh, providing near to the additional US $ 1 million in funding to advance understanding of the Nipah virus
Sapio announces the first web-based bioanalysis LIMS solution
By IPP Bureau - March 16, 2022
This pre-packaged release is a ready-to-go solution with powerful, straightforward bioanalysis pipeline support
Experts call for capacity building to combat Antimicrobial Resistance
By IPP Bureau - March 16, 2022
The meeting was co-organized by World Health Organization’s Country Office for India, World Animal Protection India and ReAct Asia Pacific
Unichem receives ANDA approval for hypertension drug
By IPP Bureau - March 16, 2022
Nebivolol is used alone or together with other medicines to treat high blood pressure
Wockhardt’s novel antibiotic Phase 1 trial to be conducted by NIH, USA
By IPP Bureau - March 16, 2022
The USFDA has granted a qualified infectious disease product (QIDP) designation to WCK 6777, which signifies its ability to meet unmet medical needs and facilitates a faster approval process
Sanofi announces €300 million collaboration with Blackstone Life Sciences
By IPP Bureau - March 16, 2022
The investment will accelerate the overall Sarclisa development program
Jeffrey W. Fisher is the recipient of the Arnold J Lehman SOT award
By IPP Bureau - March 16, 2022
Career achievement for contributions in Physiologically based pharmacokinetic (PBPK) and biologically based does response (BBDR) modelling tools
IQVIA launches OCE+ to deliver AI-driven customer engagement
By IPP Bureau - March 16, 2022
OCE+ uses IQVIA’s industry-leading data and advanced analytics to deliver AI-driven recommendations directly into the daily workflows of life sciences commercial teams
Oppilotech and Evariste technologies partner for anti-bacterial programme
By IPP Bureau - March 16, 2022
Machine learning approach to systems biology combined with ligand discovery platform
UFDA approves first generic of Symbicort to treat asthma and COPD
By IPP Bureau - March 16, 2022
This drug-device combination product is a metered-dose inhaler (MDI), which contains both budesonide (a corticosteroid that reduces inflammation) and formoterol (a long-acting bronchodilator that relaxes muscles in the airways to improve breathing)
Onco aims to make cancer care affordable
By IPP Bureau - March 16, 2022
Onco Care Plus is available at just INR 399 per month, and provides services like free doctor consultation, 15% off on cancer treatment costs, 25% off for diagnostic tests, free nutrition plans, among many more
Sanofi and Seagen to jointly develop multiple novel antibody-drug conjugates
By IPP Bureau - March 16, 2022
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
Bharat Biotech and Biofabri to develop and distribute novel TB vaccine
By IPP Bureau - March 16, 2022
MTBVAC is a global public-private project that will be a milestone in the field of vaccinology
SRL Diagnostics and Roche Diagnostics partner to establish an integrated lab
By IPP Bureau - March 16, 2022
Empowers the lab to do more in less time within the existing floor plan by integrating clinical chemistry and immunoassay testing onto a single platform
Boston Scientific opens second R&D centre in Pune
By IPP Bureau - March 16, 2022
The centre will initially employ 170 engineers, bringing the total number of Boston Scientific’s R&D employees in India to more than 300
